Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care?
The aim of this study was to assess hormone replacement therapy (HRT) and bone care health maintenance practices for cervical cancer patients with iatrogenic menopause, and, secondarily, to investigate the potential impact of specific demographic and clinical factors. Women diagnosed with iatrogenic menopause due to cervical cancer treatment between January 1, 2005 and December 31, 2015 were identified from the University of Virginia's tumor registry. Univariable data were analyzed using Wilcoxon rank sum, Chi square, and Fisher's exact test; multivariable analysis was conducted using logistic regression. Two hundred and two women were included for analysis. Ninety-seven of these women (48.0%) received counseling and/or a prescription for HRT. After multivariable analysis, older age at diagnosis (adjusted OR 0.940, 95% CI 0.890-0.993, p=0.0270) and uninsured payer status (adjusted OR 0.455, 95% CI 0.212-0.977, p=0.0435) were associated with a decreased likelihood of receiving counseling or a prescription for HRT. A longer duration of follow-up was associated with the primary outcome with an adjusted OR of 1.011 (95% CI 1.001-1.020, p=value 0.0252). Dual-energy X-ray absorptiometry scans (DEXA) were infrequent and received by only 17/197 (8.6%) of all women. Fewer than half of all women received counseling and/or a prescription for HRT after diagnoses of iatrogenic menopause, and disparities were noted based on insurance status. These findings reflect a need for clearer guidelines on HRT during survivorship and improved efforts to reduce disparities in the distribution of survivorship care.